IGC Pharma (IGC)
XASE:IGC
Want to see IGC full AI Analyst Report?
IGC Stock Chart & Stats
$0.30
>-$0.01(-2.38%)
At close: 4:00 PM EST
$0.30
>-$0.01(-2.38%)
Day’s Range― - ―
52-Week Range$0.24 - $0.50
Previous CloseN/A
Volume646.33K
Average Volume (3M)715.71K
Market Cap
$26.68M
Enterprise Value$28.31M
Total Cash (Recent Filing)$235.00K
Total Debt (Recent Filing)$926.00K
Price to Earnings (P/E)―
Beta0.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding100,091,320
10 Day Avg. Volume826,885
30 Day Avg. Volume715,709
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue23.87
Enterprise Value/Gross Profit80.44
Enterprise Value/Ebitda-4.59
Forecast
1Y Price Target
$5.50Price Target Upside1733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Debt-free Balance SheetHaving essentially zero reported debt in the trailing twelve months materially lowers fixed financial obligations and interest risk. Over the next several months this structural strength preserves financial flexibility to fund R&D or negotiate financing without immediate debt-service pressure, improving solvency resilience while clinical programs advance.
Clinical Trial Advancement (Phase 2 CALMA)Progress toward completing a Phase 2 trial is a durable operational positive: site addition at a leading academic center and ~80% participant completion reduce execution risk and raise the probability of a readable data set. A near-term data readout would materially de-risk the core program and clarify regulatory and partnering prospects.
Access To Committed $12M Credit FacilityMaintaining a $12M facility under largely preserved terms secures liquidity optionality for operational needs and trial completion. This structural financing access reduces immediate solvency pressure, enabling management to focus on clinical execution and strategic partnerships rather than urgent fundraising over the next several months.
Bears Say
Sharp Revenue Decline And Negative MarginsA dramatic revenue contraction combined with extremely negative operating and net margins signals the company is not generating scalable commercial economics. Over a multi-month horizon this structural profitability shortfall impedes reinvestment, heightens dilution risk, and makes sustaining R&D spending dependent on external capital or partnerships.
Persistent Negative Operating Cash FlowContinued negative operating and free cash flow means the business cannot self-fund development. This structural cash burn requires ongoing financing to support trials and operations; if financing terms tighten or capital markets become constrained, program pacing and trial completion could be disrupted over the next several months.
Eroding Shareholder Equity And Capital CushionSubstantial erosion of equity over time reduces the company’s buffer against setbacks and increases vulnerability to dilution when raising capital. Structurally, a diminished capital cushion limits strategic optionality and raises the probability that future financing will be required on dilutive or costly terms if clinical or regulatory progress stalls.
IGC Pharma News
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.24 and its highest was $0.50 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $26.68M.
When is IGC Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were IGC Pharma’s earnings last quarter?
Currently, no data Available
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 100,091,320 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IGC Pharma
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGC Stock 12 Month Forecast
Average Price Target
$5.50
▲(1733.33% Upside)
Technical Analysis
Ownership Overview
9.70% Insiders
1.37% Mutual Funds
0.22% Other Institutional Investors
87.28% Public Companies and
Individual Investors